Molecular approaches for targeted drug delivery towards cancer: A concise review with respect to nanotechnology

被引:38
作者
Das Kurmi, Balak [1 ]
Patel, Preeti [1 ]
Paliwal, Rishi [2 ]
Paliwal, Shivani Rai [1 ]
机构
[1] Guru Ghasidas Vishwavidyalaya, SLT Inst Pharmaceut Sci, Bilaspur, CG, India
[2] Indira Gandhi Natl Tribal Univ, Dept Pharm, Nanomed & Bioengn Res Lab, Amarkantak, MP, India
关键词
NF-KAPPA-B; NANOPARTICLES INDUCE APOPTOSIS; TUMOR-ASSOCIATED MACROPHAGES; SELECTIVE BCL-2 INHIBITOR; RECEPTOR TYROSINE KINASES; HUMAN MONOCLONAL-ANTIBODY; TRAIL-INDUCED APOPTOSIS; BREAST-CANCER; GROWTH-FACTOR; ANTITUMOR-ACTIVITY;
D O I
10.1016/j.jddst.2020.101682
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cancer is a leading cause of human death throughout the world. The lack of specificity associated with conventional anti-cancer therapeutics leads to several side effects in addition. Cancer initiation and progression involve complex and multi carcinogenesis processes along with diverse cellular physiological system activities like cell signaling and apoptosis. An erratic microenvironment and drug resistance mechanism of cancer cells further causes failure of the most conventional chemotherapy regimen. Such limitations of the conventional cancer therapy advocate well engineered and smart therapeutics for cancer treatment. An ideal cancer treatment needs a customized and specialized drug delivery technology, which is capable to eradicate even a last cancer cell that may be responsible for the relapse of disease. Targeted nanocarriers (NCs) navigate the loaded therapeutics towards the specific site of action with the reduced adverse effects on the healthy cells. This review presents an overview of various molecular mechanisms and cellular alterations associated with cancer cell development and how targeted formulations can be designed for cancer therapy. A brief focuses on the applications of nanotechnology to exploit these mechanisms and molecular ports for the development of a novel targeted formulation for cancer treatment has also been discussed. © 2020 Elsevier B.V.
引用
收藏
页数:22
相关论文
共 333 条
[1]  
Abou-Nassar Karim, 2010, Clin Adv Hematol Oncol, V8, P886
[2]   A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo [J].
Abulwerdi, Fardokht ;
Liao, Chenzhong ;
Liu, Meilan ;
Azmi, Asfar S. ;
Aboukameel, Amro ;
Mady, Ahmed S. A. ;
Gulappa, Thippeswamy ;
Cierpicki, Tomasz ;
Owens, Scott ;
Zhang, Tao ;
Sun, Duxin ;
Stuckey, Jeanne A. ;
Mohammad, Ramzi M. ;
Nikolovska-Coleska, Zaneta .
MOLECULAR CANCER THERAPEUTICS, 2014, 13 (03) :565-575
[3]   Ligand based dendritic systems for tumor targeting [J].
Agarwal, Abhinav ;
Saraf, Surbhi ;
Asthana, Abhay ;
Gupta, Umesh ;
Gajbhiye, Virendra ;
Jain, Narendra K. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2008, 350 (1-2) :3-13
[4]   Targeted anticancer therapy: Overexpressed receptors and nanotechnology [J].
Akhtar, Mohd Javed ;
Ahamed, Maqusood ;
Alhadlaq, Hisham A. ;
Alrokayan, Salman A. ;
Kumar, Sudhir .
CLINICA CHIMICA ACTA, 2014, 436 :78-92
[5]   SWCNTs as novel theranostic nanocarriers for cancer diagnosis and therapy: towards safe translation to the clinics [J].
Al Faraj, Achraf .
NANOMEDICINE, 2016, 11 (11) :1431-1445
[6]   Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth [J].
Al-Jamal, Khuloud T. ;
Al-Jamal, Wafa' T. ;
Akerman, Simon ;
Podesta, Jennifer E. ;
Yilmazer, Acelya ;
Turton, John A. ;
Bianco, Alberto ;
Vargesson, Neil ;
Kanthou, Chryso ;
Florence, Alexander T. ;
Tozer, Gillian M. ;
Kostarelos, Kostas .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (09) :3966-3971
[7]   Tumor targeted micellar nanocarriers assembled from epipodophyllotoxin-based amphiphiles [J].
Alliot, Julien ;
Theodorou, Ioanna ;
Dinh-Vu Nguyen ;
Forier, Cynthia ;
Duconge, Frederic ;
Gravel, Edmond ;
Doris, Eric .
NANOSCALE, 2019, 11 (19) :9756-9759
[8]   Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL [J].
Altucci, L ;
Rossin, A ;
Raffelsberger, W ;
Reitmair, A ;
Chomienne, C ;
Gronemeyer, H .
NATURE MEDICINE, 2001, 7 (06) :680-686
[9]   Olaratumab: A Novel Platelet-Derived Growth Factor Receptor -Inhibitor for Advanced Soft Tissue Sarcoma [J].
Andrick, Benjamin J. ;
Gandhi, Arpita .
ANNALS OF PHARMACOTHERAPY, 2017, 51 (12) :1090-1098
[10]  
[Anonymous], PHOSPHATASES THEIR R